BL 7040

Drug Profile

BL 7040

Alternative Names: BL7040

Latest Information Update: 27 Aug 2015

Price : $50

At a glance

  • Originator Hebrew University of Jerusalem; Yissum Research Development Company
  • Developer BioLineRx; Ester Neurosciences
  • Class Anti-inflammatories; Oligonucleotides
  • Mechanism of Action Acetylcholinesterase inhibitors; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Discontinued Myasthenia gravis

Most Recent Events

  • 27 Aug 2015 BL 7040 is still in phase-II development for Ulcerative colitis in Israel
  • 17 Mar 2014 BL 7040 is available for licensing as of 17 Mar 2014. http://www.biolinerx.com/
  • 17 Mar 2014 Adverse events data from preclinical studies released in the BioLineRx Form 20-F
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top